Maze Therapeutics insider sells 15,000 shares

Maze Therapeutics executive Harold Bernstein, President, R&D & CMO, exercised stock options to acquire 15,000 shares of common stock at an exercise price of $10.42 per share on April 1, 2026.

Rhea-AI Filing Summary

Maze Therapeutics executive Harold Bernstein, President, R&D & CMO, exercised stock options to acquire 15,000 shares of common stock at an exercise price of $10.42 per share on April 1, 2026. He then sold the same 15,000 shares in open-market transactions at weighted average prices of $29.24, $30.06, and $31.07 per share pursuant to a pre-arranged Rule 10b5-1 trading plan. Following these transactions, his direct common stock holdings from this block were reduced to zero, while he continued to hold 237,407 stock options after the exercise.

Insider Trade Summary 10b5-1

Exercise and Sale: 15,000 shares ($286K approx. pre-tax spread)

Exercise and Sale 5 txns

Insider Bernstein Harold

Role President, R&D & CMO

Sold 15,000 shs ($442K)

Approx. gross sale proceeds $442K

Approx. exercise cost $156K

Approx. pre-tax spread $286K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	15,000	$0.00	$0.00
Exercise	Common Stock	15,000	$10.42	$156K
Sale	Common Stock	11,352	$29.2414	$332K
Sale	Common Stock	3,348	$30.0585	$101K
Sale	Common Stock	300	$31.0667	$9K

Holdings After Transaction: Stock Option (Right to Buy) — 237,407 contracts (Direct); Common Stock — 0 shares (Direct)

Footnotes (5)

1. F1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
2. F2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.77 to $29.75 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 and 4 of this Form 4.
3. F3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.77 to $30.50 per share, inclusive.
4. F4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.80 to $31.22 per share, inclusive.
5. F5. The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

Key Figures

Options exercised: 15,000 shares Exercise price: $10.42 per share Shares sold at $29.2414: 11,352 shares +4 more

7 metrics

Options exercised 15,000 shares Stock Option (Right to Buy) exercised on April 1, 2026

Exercise price $10.42 per share Exercise price of stock options for 15,000 shares

Shares sold at $29.2414 11,352 shares Common stock open-market sale on April 1, 2026

Shares sold at $30.0585 3,348 shares Common stock open-market sale on April 1, 2026

Shares sold at $31.0667 300 shares Common stock open-market sale on April 1, 2026

Total shares sold 15,000 shares Net open-market sales on April 1, 2026

Options remaining 237,407 options Stock options held after the exercise transaction

Key Terms

Rule 10b5-1 trading plan, Stock Option (Right to Buy), weighted average price, open-market sale, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)" in the derivative transaction"

weighted average price financial

"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action: "open-market sale" for the common stock transactions"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

vesting financial

"The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did MAZE executive Harold Bernstein report?

Harold Bernstein exercised options for 15,000 Maze Therapeutics shares at $10.42 each, then sold all 15,000 shares in open-market trades around the $29–31 range, according to his Form 4 filing with the Securities and Exchange Commission.

At what prices did Harold Bernstein sell MAZE common stock?

Bernstein sold 15,000 Maze Therapeutics common shares in three tranches at weighted average prices of $29.2414, $30.0585, and $31.0667 per share, with each tranche consisting of 11,352, 3,348, and 300 shares, respectively, on April 1, 2026.

Were Harold Bernstein’s MAZE stock sales under a Rule 10b5-1 plan?

Yes. A footnote states the transactions were effected under a Rule 10b5-1 trading plan adopted on September 29, 2025, indicating the sales were pre-arranged rather than discretionary, which can lessen the information value of their specific timing for investors.

How many MAZE options does Harold Bernstein hold after these transactions?

After exercising 15,000 options at a $10.42 exercise price, Bernstein held 237,407 Maze Therapeutics stock options. This figure represents his remaining derivative position from this grant structure as of the April 1, 2026 Form 4 disclosure.

Did Harold Bernstein retain any MAZE common shares after the reported sales?

For the reported block, his direct Maze Therapeutics common stock holdings declined to zero, as shown by the final transaction row’s post-transaction balance of 0 shares following the sale of the last 300 shares at a weighted average price of $31.0667.

What were the key terms of the exercised MAZE stock option?

The exercised Maze Therapeutics option covered 15,000 underlying common shares at an exercise price of $10.42 per share and had an original expiration date of October 26, 2032, with vesting tied to continued service and monthly vesting after an initial one-quarter cliff.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/02/2026 - 04:08 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bernstein Harold

(Last) (First) (Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, R&D & CMO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/01/2026		M(1)		15,000	A	$10.42	15,000	D
Common Stock	04/01/2026		S(1)		11,352	D	$29.2414(2)	3,648	D
Common Stock	04/01/2026		S(1)		3,348	D	$30.0585(3)	300	D
Common Stock	04/01/2026		S(1)		300	D	$31.0667(4)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$10.42	04/01/2026		M(1)			15,000	(5)	10/26/2032	Common Stock	15,000	$0	237,407	D

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.77 to $29.75 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 and 4 of this Form 4.

3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.77 to $30.50 per share, inclusive.

4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.80 to $31.22 per share, inclusive.

5. The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

	/s/ Courtney Phillips, as attorney-in-fact	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)